Vertaling van "UK " (Nederlands → Frans) :

UK CJD Disease Surveillance Unit, [http ...]
UK CJD Disease Surveillance Unit, [http ...]

Acknowledgements: Brekelmans C (GGZNederland, NL), Hewson L (Bradford Counseling Service, UK), Kelvin R (Department of Health, UK), Kingsbury S (CAMHS Hertfordshire Partnership Trust, UK), Kutcher S (Dalhousie University, Ca), Leys M (VUB, Be), Menting J (Yulius Mental Health, NL), Minotte P (IWSM, Be), Rees D (Independent Development Consultant, UK), Rietveld AA (Accare Univerity Centre for child and adolescent psychiatry, NL), Van Nuffel R (VVGG, Be), Waddell C (Simon Fraser University, Ca), Wijnands Y (Ministry of Health, Wellbeing and Sports, NL), York A (South West London & St George’s Mental Health NHS Trust, UK), Garcin, V (EPSM Lille-Métropole, FR)
Remerciements: Brekelmans C (GGZNederland, NL), Hewson L (Bradford Counseling Service, UK), Kelvin R (Department of Health, UK), Kingsbury S (CAMHS Hertfordshire Partnership Trust, UK), Kutcher S (Dalhousie University, Ca), Leys M (VUB, Be), Menting J (Yulius Mental Health, NL), Minotte P (IWSM, Be), Rees D (Independent Development Consultant, UK), Rietveld AA (Accare Univerity Centre for child and adolescent psychiatry, NL), Van Nuffel R (VVGG, Be), Waddell C (Simon Fraser University, Ca), Wijnands Y (Ministry of Health, Wellbeing and Sports, NL), York A (South West London & St George’s Mental Health NHS Trust, UK), Garcin, V (EPSM Lille-Métropole, FR)

Table 8: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)
Table 10: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)

- Department of Health (DH), UK o [http ...]
- Department of Health (DH), UK o [http ...]

Gerard et al. Women from UK aged 40-64 (1999) 83 EQ-5D years (eligible for screening) UK tariffs (general population) True negative 0.940 At the breast screening Most women are nervous, but are not anxious or depressed. clinic
At the breast screening Most women are nervous, but are not anxious or depressed. Gerard et al. Women from UK aged 40-64

De websites van de volgende organisaties werden bezocht: Belgian Health Council, European Union law, EUROCJD, Department of Health UK, UK CJD Disease Surveillance Unit, Spongiform Encefalopathy Advisory Committee (SEAC), EMEA, FDA,WHO.
Les sites internet des organisations suivantes ont également été explorés: Belgian Health Council, European Union law, EUROCJD, Department of Health UK, UK CJD Disease Surveillance Unit, Spongiform Encefalopathy Advisory Committee (SEAC), EMEA, FDA,WHO.

Het nummer tussen [ ] verwijst naar de primaire bron en is dus terug te vinden in de referentielijst van de NICE richtlijn (zie: [http ...]
Le chiffre entre [ ] désigne la source primaire et peut donc être retrouvé dans la liste de références de la directive du NICE (voir : http ://www.rcog.org.uk/resources/Public/Antenatal_Care.pdf, p. 260- 278).

In dit geval kan de primaire bron dus worden teruggevonden in de „references‰-lijst van de NICE richtlijn (zie: [http ...]
Dans ce cas, la source primaire peut donc être retrouvée dans la liste ÿ references Ÿ de la directive du NICE (voir : http ://www.rcog.org.uk/resources/Public/Antenatal_Care.pdf, p260-278).

A systematic review of the evidence for telemedicine in burn care: with a UK perspective.
Do burn patients need burn specific multidisciplinary outpatient aftercare: research results.

ONE OR OTC PAP PAPP-A PCR PHLS PIH PPI PPV PROM RAADP RCOG RCT Ref RhD RIBA RIZIV RNA RPG RPR RR RST SD SETS SFH SGA SIGN SOA SOGC SPD TPHA TSH uE3 UK US CDC Prevention USPSTF USS UTI VDRL VE VLOV VVOG WGO WHO WMD WVVH
OGTT ONE OR OTC PAP PAPP-A PCR PHLS PIH PPI PPV PROM RAADP RCOG RCT Ref RhD RIBA RIZIV RNA RPG RPR RR RST SD SETS SFH SGA SIGN SOA SOGC SPD TPHA TSH uE3 UK US CDC USPSTF USS UTI VDRL VE VLOV VVOG WGO WHO WMD WVVH